TME Pharma announces new treasury investment policy

- **Part of treasury funds can now be allocated to cryptocurrency-linked investments**
- **If successful, the company may consider expanding cryptocurrency strategies beyond treasury management to make it part of the core mission**
- **These treasury management activities are designed to support TME's mission of developing new therapies for diseases with high unmet need**

Berlin, Germany, 30 June 2025, 18h00 – **TME Pharma N.V. (Euronext Growth Paris: ALTME),** a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer and eye-diseases, announced today that is has changed its treasury management investment policy to allow investment in higher-risk assets such as crypto-currency linked investments. The decision made, was possible because TME is now well positioned for the coming 12 months after it installed a new strategy and after the execution of a reorganization and a non-dilutive financing in May. TME will continue to explore various opportunities to further support TME's mission to develop new therapies for diseases with high unmet needs including its lead drug candidate NOX-A12 (olaptesed pegol, an anti-CXCL12 L-RNA aptamer) in newly diagnosed brain cancer and NOX-E36 in ophthalmic diseases.

This strategy aims to leverage the extensive investment expertise of the newly named CEO, Diede van den Ouden. If these treasury management activities prove successful, the company may consider broadening the corporate mission to include crypto investment activities as a means to support the R&D mission of the company after seeking appropriate regulatory and shareholder approvals necessary for such a change.

"Since I bring strong investment experience to TME, one of the ways I can support TME's mission is by better managing its treasury investments. I see a lot of investor interest in crypto holding companies, and I believe this could be an interesting opportunity for TME to leverage some of the cash not currently needed. The near-term treasury investment should increase our capacity for R&D projects aligned with the company's core mission," said Diede van den Ouden, the newly named CEO of TME Pharma.

For more information, please contact:

TME Pharma N.V.
Diede van den Ouden, CEO
Tel. +49 (0) 30 16637082 0
ir@tmepharma.com

About TME Pharma

TME Pharma is a clinical-stage company focused on developing novel therapies for treatment of the most aggressive cancers. The company's oncology-focused pipeline is designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. By neutralizing chemokines in the TME, *TME Pharma's* approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. In the GLORIA Phase 1/2 clinical trial, *TME Pharma* is studying its lead drug candidate NOX-A12 (olaptesed pegol, an anti-CXCL12 L-RNA aptamer) in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. *TME Pharma* has delivered top-line data from the NOX-A12 three dose-escalation cohorts combined with radiotherapy of the GLORIA clinical trial, observing consistent tumor reductions and objective tumor responses. Additionally, GLORIA expansion arms evaluate safety and efficacy of NOX-A12 in other combinations where the interim results from the triple combination of NOX-A12, radiotherapy and bevacizumab suggest even deeper and more durable responses, and improved survival. US FDA and the German BfArM have approved the design of a randomized Phase 2 trial in glioblastoma and *TME Pharma* was awarded fast track designation by the FDA for NOX-A12 in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer, glioblastoma. NOX-A12 in combination with radiotherapy had also previously received orphan drug designation (ODD) for glioblastoma in the United States and glioma in Europe. *TME Pharma* has delivered final top-line data with encouraging overall survival and safety profile from its NOX-A12 combination trial with Keytruda® in metastatic colorectal and pancreatic cancer patients, which was published in the Journal for ImmunoTherapy of Cancer in October 2021. The company has entered in its second collaboration with MSD/Merck for its Phase 2 study, OPTIMUS, to further evaluate safety and efficacy of NOX-A12 in combination with Merck's Keytruda® and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The design of the trial has been approved in the United States. The company's second clinical-stage drug candidate, NOX-E36 (emapticap pegol, L-RNA aptamer inhibiting CCL2 and related chemokines), showing potential to address fibrosis and inflammation is evaluated in ophthalmic diseases with a high need for well-tolerated therapies with anti-fibrotic effect. Further information can be found at: www.tmepharma.com.

Visit *TME Pharma* on LinkedIn and X.

About the GLORIA Study

GLORIA (NCT04121455) is *TME Pharma's* dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates safety and efficacy of NOX-A12 in the expansion arm in which NOX-A12 is combined with radiotherapy and bevacizumab.

About the OPTIMUS Study

OPTIMUS (NCT04901741) is *TME Pharma's* planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.

Disclaimer

Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain "forward-looking statements." Forward-looking statements are based on *TME Pharma's* current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and *TME Pharma's* ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made as of this date, and *TME Pharma* undertakes no duty to update such information except as required under applicable law.